• New INTEGUMENT-INFANT trial results demonstrate improvements in itch, reductions in symptoms, and improvements in quality of life for infants with atopic dermatitis and their families
• Findings further support investigational ZORYVE cream 0.05% to help address unmet needs in infants aged 3 to <24 months
• 60% of children develop atopic dermatitis symptoms within their first year of life
   

WESTLAKE VILLAGE, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new caregiver-reported outcomes data from the INTEGUMENT-INFANT trial supporting ZORYVE® (roflumilast) cream 0.05% in the treatment of infants with mild to moderate atopic dermatitis ages 3-24 months presented at the American College of Allergy, Asthma & Immunology's (ACAAI) Annual Scientific Meeting, taking place Nov. 12-16 in Phoenix, Arizona.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.